Octagon Therapeutics Was A Biotechnology Company Dedicated To Developing Treatments For Autoimmune And Inflammatory Diseasesfounded On Scientific Insights From Harvardthe Company Operated In Providenceriand Cambridgemawith Lab Space At The Engine In Cambridgeoctagon Focused On Addressing Severe Autoimmune Conditions Such As Systemic Lupus Erythematosusmultiple Sclerosissjogrenae S Syndromeand Myositis The Company Aimed To Modulate The Glycoproteome To Identify Disease Driving Pathways And Create Targeted Therapiesnotable Projects Included Oct50A B Cell Immunomodulator Designed To Restore The Regulatory Function Of Siglec 2And Oct102A Preclinical Asset Targeting An Undisclosed Checkpoint Receptoroctagon Also Engaged In Research Collaborationsincluding A Partnership With Novo Nordisk To Explore Cardiometabolic Disease Targetsleadership Included Co Founder And Ceo Isaac Stonersupported By A Board Of Directors With Expertise In Venture Capital And Biotechdespite Early Progressoctagon Ceased Operations In April 2025 Due To Challenges In Its Research And Development Pipeline
No conferences found for this company.
| Company Name | Octagon Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
